Cochrane Review Group

Heart

140 systematic reviews in Heart ask 1,554 questions. 17.5% have no studies to answer them, 21.2% rest on very low certainty evidence and 28.6% reach moderate or high certainty.

Reviews

140

Questions

1,554

current versions

No studies

17.5%

Moderate or high

28.6%

No studies 272 · 17.5%Ungraded 44 · 2.8%Very low 329 · 21.2%Low 464 · 29.9%Moderate 319 · 20.5%High 126 · 8.1%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Search questions in Heart

Thinnest evidence

All no studies and very low questions

Question	Effect	Evidence	Status / GRADE
Exercise‐based cardiac rehabilitation vs usual care HRQoL (all measurement scales) · adults with heart failure Exercise‐based cardiac rehabilitation for adults with heart failure (2024) · Cochrane	no estimate extracted	33 studies · 4769 participants	Very low
Prophylactic corticosteroids vs placebo or no corticosteroids Length of hospital stay (measured in days, during the index hospital admission) · adults diagnosed with coronary artery disease or cardiac valve disease, and candidates for cardiac surgery with… Prophylactic corticosteroids for cardiopulmonary bypass in adult cardiac surgery (2024) · Cochrane	no estimate extracted	25 studies · 1841 participants	Very low
Mobile phone text messaging vs usual care Medication adherence (self‐reported adherence, questionnaire, tablet counts, medication event monitoring systems, pharmacy prescription data) · people with established arterial occlusive events Mobile phone text messaging for medication adherence in secondary prevention of cardiovascular disease (2024) · Cochrane	no estimate extracted	18 studies · 8136 participants	Very low
Mobile phone text messaging vs usual care Non‐fatal cardiovascular events (percentage of people having non‐fatal cardiovascular events) · people with established arterial occlusive events Mobile phone text messaging for medication adherence in secondary prevention of cardiovascular disease (2024) · Cochrane	no estimate extracted	NR	Very low
Mobile phone text messaging vs usual care Combined CVD events (percentage of people having combined CVD events) · people with established arterial occlusive events Mobile phone text messaging for medication adherence in secondary prevention of cardiovascular disease (2024) · Cochrane	no estimate extracted	NR	Very low
Mobile phone text messaging vs usual care Low‐density lipoprotein cholesterol (mg/dL) (endpoint low‐density lipoprotein cholesterol reading) · people with established arterial occlusive events Mobile phone text messaging for medication adherence in secondary prevention of cardiovascular disease (2024) · Cochrane	no estimate extracted	8 studies · 4983 participants	Very low
Mobile phone text messaging vs usual care Blood pressure (mmHg) (endpoint blood pressure reading) · people with established arterial occlusive events Mobile phone text messaging for medication adherence in secondary prevention of cardiovascular disease (2024) · Cochrane	no estimate extracted	8 studies · 5173 participants	Very low
Mobile phone text messaging vs usual care Heart rate (beats per minute) (endpoint heart rate reading) · people with established arterial occlusive events Mobile phone text messaging for medication adherence in secondary prevention of cardiovascular disease (2024) · Cochrane	no estimate extracted	4 studies · 2946 participants	Very low
Mindfulness‐based interventions (MBIs) vs active comparators Clinical CVD events · people at high risk of or withcardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane	no estimate extracted	NR	No studies
Mindfulness‐based interventions (MBIs) vs non‐active comparators Clinical CVD events (CVD mortality and non‐fatal MI) · people at high risk of or withcardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane	RR 0.94 [0.37, 2.42]	1 study · 110 participants	Very low
Transcendental meditation (TM) vs active comparators Perceived stress, change from baseline · people at high risk of or with cardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane	no estimate extracted	3 studies · 194 participants	Very low
Transcendental meditation (TM) vs active comparators Well‐being · people at high risk of or with cardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane	no estimate extracted	NR	No studies

Reviews 140

Systematic versus opportunistic risk assessment for the primary prevention of cardiovascular disease

Dyakova, M, Shantikumar, S, et al. · Cochrane Database of Systematic Reviews · 2016

Heart

Thinnest evidence

Reviews 140

Systematic versus opportunistic risk assessment for the primary prevention of cardiovascular disease

Sexual counselling for sexual problems in patients with cardiovascular disease

Colchicine for prevention of cardiovascular events

Implantable loop recorder versus conventional diagnostic workup for unexplained recurrent syncope

Concomitant atrial fibrillation surgery for people undergoing cardiac surgery

Efficacy and safety of ablation for people with non‐paroxysmal atrial fibrillation

Hormone therapy for preventing cardiovascular disease in post‐menopausal women

Transmyocardial laser revascularization versus medical therapy for refractory angina

Hyperbaric oxygen therapy for acute coronary syndrome

Stem cell treatment for acute myocardial infarction

Aminophylline for bradyasystolic cardiac arrest in adults

Structured telephone support or non‐invasive telemonitoring for patients with heart failure

Fresh frozen plasma for cardiovascular surgery

Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death

Preoperative statin therapy for patients undergoing cardiac surgery

Prophylactic lidocaine for myocardial infarction

Internet‐based interventions for the secondary prevention of coronary heart disease

Effectiveness of the Valsalva Manoeuvre for reversion of supraventricular tachycardia

Fibrates for secondary prevention of cardiovascular disease and stroke

Nurse‐led titration of angiotensin converting enzyme inhibitors, beta‐adrenergic blocking agents, and angiotensin receptor blockers for people with heart failure with reduced ejection fraction

Tong‐xin‐luo capsule for patients with coronary heart disease after percutaneous coronary intervention

Multiple risk factor interventions for primary prevention of cardiovascular disease in low‐ and middle‐income countries

Implantable defibrillators versus medical therapy for cardiac channelopathies

Effects of total fat intake on body weight

Heparin versus placebo for non‐ST elevation acute coronary syndromes